HealthCare Global Enterprises Ltd. Reports Q4 & FY24 Results
HealthCare Global Enterprises Limited (“HCG"),the leader in India in speciality healthcare services focused on oncology and fertility today announced its audited financial results for the quarter (“Q4")and full year ended FY24.
Highlights for quarter endedMarch 31st, 2024INR million except earnings per sharePeriod ended Mar’24Q4-FY24Q4-FY23(1)Growth
(y-o-y)4,9464,41712%94177821%19.0%17.6%92076321%18.6%17.3%282131115%5.7%3.0%21384154%4.3%1.9%1.50.6
(1) Q4 FY23 includes Revenue & EBITDA from discontinued MSR operations, adjusted Revenue growth stands at 14% &EBITDA growth stands at 23%
(2) Adjusted EBITDA excluding ESOPs and Onetime Expense
(3) PAT after Minority InterestCommenting on the results,Dr. B.S. Ajaikumar, Executive Chairman, HealthCare Global Enterprises Ltd.said,“We experience a deep sense of fulfilment to report a consistent benchmark-beating performance across all fronts for the quarter and the fiscal year ending FY24. Year after year, HCG has achieved sustainable cancer care outcomes comparable to premier centers in the world, thanks to our unique value-based care model and focused factory approach providing patients with the right treatment at the right time, using best in class talent, knowledge, technology, and infrastructure.
Given the mounting incidence of cancer in recent years, India has prudently enhanced its cancer diagnosis and treatment processes in the guiding light of visionary crusaders like HCG. We prioritize a deep engagement in academics and research alongside an unflinching focus on patient outcomes. In the past year, we have made significant triumphs, including the successful completion if comprehensive genomic profiling for over 1,000 cancer patients, executing complex surgeries, and launching
